Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT04429087
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
- NCT04429087 ↗
- Active, not recruiting
- Boehringer Ingelheim
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT04429087 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04429087 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A First-In-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Administered by Parenteral Route in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
- Interventions
- Obrixtamig - parenteral 1; Obrixtamig - parenteral 2
- Arms
- Arm 1: Obrixtamig · Experimental
- Arm 2: Obrixtamig · Experimental
- Enrollment
- 306
- Primary outcomes
- Arm 1 and Arm 2: Maximum tolerated dose (MTD)
- Arm 1 and Arm 2: Number of patients with DLTs in the MTD evaluation period
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 29, 2020
- Primary completion
- Aug 31, 2026
- Results posted
- No
- Registry record
- NCT04429087 · updated Sep 21, 2026
Publications
linked from the registry- Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed ZO, Liu M, Studeny M, Owonikoko TK. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol. 2022 Aug;18(24):2639-2649. doi: 10.2217/fon-2022-0196. Epub 2022 Jul 11. PubMed 35815644